sponsored
PatientsVille.com Logo

PatientsVille

Adempas Medical Research Studies

Up-to-date List of Adempas Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Adempas Medical Research Studies

Rank Status Study
1 Recruiting Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (Adempas, BAY63-2521)
Outcome Measures: Number of participants with treatment emergent adverse events and adverse drug reactions;   Change in 6-Minute Walking Distance;   Time to Clinical Worsening
2 Recruiting Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
Conditions: Hypertension, Pulmonary;   Altitude Sickness
Intervention: Drug: Riociguat
Outcome Measures: Change from Baseline in Pulmonary Artery Pressure;   Change from Baseline in Radial Arterial Pressure;   Change from Baseline in Arterial Oxygen Saturation (PaO2);   Change from Baseline in Ventilation Rate;   Change from Baseline in Work Rate at Exhaustion;   Change from Baseline in Cardiac Output
3 Recruiting Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Condition: Cystic Fibrosis
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
Outcome Measures: Change of sweat chloride content from baseline to day 14;   Change of sweat chloride content from baseline to day 28
4 Recruiting Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (Adempas, BAY63-2521)
Outcome Measures: Change from baseline in 6 minute walking distance;   Change in cardiac index;   Change in N-terminal pro-brain natriuretic peptide;   Change in World Health Organization functional class;   Proportion of patients with clinical worsening;   Change in quality of life (Qol) (EuroQol questionnaire)
5 Recruiting Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
Outcome Measures: Change in mRSS (modified Rodnan skin score);   mRSS progression rate;   mRSS regression rate;   Patient's global health assessment on a scaled rating;   Physician's global health assessment on a scaled rating;   HRQoL (health related quality of life) assessment via patient questionnaires;   Digital ulcer net burden (defined as total number of ulcers at time point minus number of ulcers at baseline);   Proportion of patients who do not develop new ulcers;   Change in FVC (forced vital capacity);   Change in DLCO (diffusion capacity of the lung for carbon monoxide);   Combined Response Index for Systemic Sclerosis (CRISS);   Number of participants with need for escape therapy
6 Recruiting Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH
Condition: Chronic Thromboembolic Pulmonary Hypertension
Intervention: Radiation: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)
Outcome Measures: Evidence of changes in glucose metabolism and myocardial RV blood flow in patients treated with riociguat using PET imaging.;   Evidence of improved RV function and volumes using 3D echocardiography and magnetic resonance imagining (MRI)
7 Recruiting EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat(BAY63-2521)
Outcome Measures: Number of adverse events/ serious adverse events;   all-cause mortality;   Number of adverse event (AE) and serious adverse event(SAE) in the different pulmonary hypertension(PH) indications (pulmonary arterial hypertension (PAH) chronic thromboembolic pulmonary hypertension(CTEPH);   6 minute walking tes;   Number of  hospitalization/outpatient visits
8 Available Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Condition: Hypertension, Pulmonary
Intervention: Drug: Adempas (Riociguat, BAY63-2521)
Outcome Measure:
9 Recruiting Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
Condition: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions: Drug: Adempas, Riociguat (BAY63-2521);   Device: Placebo
Outcome Measures: The mean change in 6 minute walking distance;   Time to clinical worsening is a composite endpoint. The composite is made up of 4 components - Time to all-cause mortality, - Time to worsening of WHO FC, - Time to 15% decrease in 6MWD, - Time to hospitalization;   Number of participants with adverse events as a measure of safety and tolerability    
10 Recruiting MOTION, Measuring Outcomes in Treatment Naive Patients
Condition: Pulmonary
Intervention: Drug: Riociguat (Adempas,BAY63-2521)
Outcome Measures: Living with Pulmonary Hypertension questionaire(LPH);   Work Limitations Questionnaire-8;   Short Form-12 questionnaire;   Living with Pulmonary Hypertension Questionnaire;   Modified Borg Dyspnea Index;   6- minutes walk distance;   WHO Functional Class;   Safety including adverse events
11 Recruiting COMPERA / COMPERA-KIDS
Conditions: Pulmonary Arterial Hypertension (PAH);   Pulmonary Hypertension (PH)
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Adempas etiology and treatment.

A major focus of Adempas research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Adempas